In a first-in-human trial, 51 healthy adults received single intravenous GB-0669 (100–2400 mg; n=36) or placebo (n=15). It was well tolerated with only mild adverse reactions, a half-life of 54 days, and dose-dependent virus neutralisation at 600 and 1200 mg.
RCTn = 51
Borriello et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix